Team: Board of Directors

Jovanka is an Australian legal practitioner with expertise in intellectual property law, corporate law, and corporate governance. She serves Australian scientific development organizations in an expert capacity on matters relating to corporate law, business operations, intellectual property development, and regulatory compliance.

Mark has over 30 years of experience in the medical diagnostics and life science industry. Much of this time has been specific to international business development, strategic planning and introduction of new technology. Through Diagnostic Technology, a company he founded, he has been responsible for the development and introduction of a number of innovative technology […]

Dianne has worked as a senior executive within the biotechnology, agritech and healthcare sectors for over twenty years and currently serves as non-executive director with Neuren Pharmaceuticals Limited (ASX: NEU) and the federal government Grains Research & Development Corporation (GRDC). She has built competitive and differentiated product portfolios, from investment in innovative research and product […]

David is currently CEO at Nanomix, a point-of-care diagnostic medical device company. David is a financial and operating executive with over 35 years of international experience in life sciences and technology companies including IDEC Pharmaceuticals, Matrix Pharmaceutical, Nanogen, and MIPS Computer Systems. His experience over 15 years in the diagnostics arena has led numerous new […]

Mike has over 36 years of experience in healthcare technology, focused on diagnostic imaging having served as Vice President and Chief Technology Officer for GE Healthcare. As the Global Technology Leader of Imaging Technologies at GE Global Research, he led the research for X-Ray, CT, MRI, Ultrasound, Nuclear Medicine, PET and Optical Imaging, and the […]

Bob has served as Chairman of the Board at Imagion Biosystems since the company’s IPO in 2017. As President and CEO of Imagion Biosystems beginning in February 2015 he led the company developing the nanoparticle-based medical imaging technology from early proof of concept through initial clinical development until June 2023. Bob’s career spans more than […]